ArticleCardiovascular drugs and therapy2018

Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials.

Harold E Bays et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.